CRESTONE, INC.
- UEI
- EDSLAP2J1BL8
- Land
- 🇺🇸 Verenigde Staten · BOULDER (803013203)
- Gewonnen opdrachten
- 21
- Totale contractwaarde
- 35 596 323 USD
- Eerste opdracht
- 23/10/2017
- Laatste opdracht
- 29/09/2022
Top 5 · Publieke aanbesteders
- Department of Health and Human Services - National Institutes of Health 🇺🇸 21 gewonnen opdrachten
CRESTONE, INC. heeft 21 overheidsopdrachten gewonnen die op Tendervue zijn geindexeerd. Bekijk hieronder de volledige lijst van aanbestedingen, publieke aanbesteders, CPV/PSC-categorieen en gegunde bedragen aan CRESTONE, INC..
Active 2017-2022
1 buyers
21 contracts
Gunningen (21)
| Datum | Aanbesteder | Omschrijving | Bedrag | Procedure |
|---|---|---|---|---|
| 29/09/2022 | Department of Health and Human Services - National Institutes of Health | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. | 140 777 USD | COST PLUS FIXED FEE |
| 20/09/2022 | Department of Health and Human Services - National Institutes of Health | TO PERFORM THE EVALUATION OF SAFETY AND EFFICACY OF CRS3123 TO TREAT CLOSTRIDIUM DIFFICILE INFECTIONS. | 4 519 619 USD | COST PLUS FIXED FEE |
| 20/09/2022 | Department of Health and Human Services - National Institutes of Health | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. | 5 768 701 USD | COST PLUS FIXED FEE |
| 28/02/2022 | Department of Health and Human Services - National Institutes of Health | TO PERFORM THE EVALUATION OF SAFETY AND EFFICACY OF CRS3123 TO TREAT CLOSTRIDIUM DIFFICILE INFECTIONS. | 0 USD | COST PLUS FIXED FEE |
| 10/12/2021 | Department of Health and Human Services - National Institutes of Health | EO14042 - TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. | 3 683 355 USD | COST PLUS FIXED FEE |
| 23/09/2021 | Department of Health and Human Services - National Institutes of Health | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. | 0 USD | COST PLUS FIXED FEE |
| 21/07/2021 | Department of Health and Human Services - National Institutes of Health | TO PERFORM THE EVALUATION OF SAFETY AND EFFICACY OF CRS3123 TO TREAT CLOSTRIDIUM DIFFICILE INFECTIONS. | 0 USD | COST PLUS FIXED FEE |
| 18/05/2021 | Department of Health and Human Services - National Institutes of Health | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. | 0 USD | COST PLUS FIXED FEE |
| 26/04/2021 | Department of Health and Human Services - National Institutes of Health | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. | 0 USD | COST PLUS FIXED FEE |
| 06/04/2021 | Department of Health and Human Services - National Institutes of Health | TO PERFORM THE EVALUATION OF SAFETY AND EFFICACY OF CRS3123 TO TREAT CLOSTRIDIUM DIFFICILE INFECTIONS. | 0 USD | COST PLUS FIXED FEE |
| 04/12/2020 | Department of Health and Human Services - National Institutes of Health | TO PERFORM THE EVALUATION OF SAFETY AND EFFICACY OF CRS3123 TO TREAT CLOSTRIDIUM DIFFICILE INFECTIONS. | 850 507 USD | COST PLUS FIXED FEE |
| 28/09/2020 | Department of Health and Human Services - National Institutes of Health | OPTIMIZATION OF POLC POLYMERASE INHIBITORS FOR TREATMENT OF HIGH PRIORITY GRAM-POSITIVE PATHOGENS. | -6 702 USD | COST PLUS FIXED FEE |
| 12/08/2020 | Department of Health and Human Services - National Institutes of Health | TO PERFORM THE EVALUATION OF SAFETY AND EFFICACY OF CRS3123 TO TREAT CLOSTRIDIUM DIFFICILE INFECTIONS. | 9 777 293 USD | COST PLUS FIXED FEE |
| 29/06/2020 | Department of Health and Human Services - National Institutes of Health | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. | 3 717 345 USD | COST PLUS FIXED FEE |
| 13/04/2020 | Department of Health and Human Services - National Institutes of Health | TO PERFORM THE EVALUATION OF SAFETY AND EFFICACY OF CRS3123 TO TREAT CLOSTRIDIUM DIFFICILE INFECTIONS. | 1 345 704 USD | COST PLUS FIXED FEE |
| 28/02/2020 | Department of Health and Human Services - National Institutes of Health | TO PERFORM THE EVALUATION OF SAFETY AND EFFICACY OF CRS3123 TO TREAT CLOSTRIDIUM DIFFICILE INFECTIONS. | 0 USD | COST PLUS FIXED FEE |
| 05/09/2019 | Department of Health and Human Services - National Institutes of Health | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | 3 439 774 USD | COST PLUS FIXED FEE |
| 29/06/2019 | Department of Health and Human Services - National Institutes of Health | IGF OT IGF - OPTIMIZATION OF POLC POLYMERASE INHIBITORS FOR TREATMENT OF HIGH PRIORITY GRAM-POSITIVE PATHOGENS. | 81 740 USD | COST PLUS FIXED FEE |
| 15/03/2019 | Department of Health and Human Services - National Institutes of Health | IGF::OT::IGF - OPTIMIZATION OF POLC POLYMERASE INHIBITORS FOR TREATMENT OF HIGH PRIORITY GRAM-POSITIVE PATHOGENS. | 0 USD | COST PLUS FIXED FEE |
| 18/09/2018 | Department of Health and Human Services - National Institutes of Health | IGF::OT::IGF - OPTIMIZATION OF POLC POLYMERASE INHIBITORS FOR TREATMENT OF HIGH PRIORITY GRAM-POSITIVE PATHOGENS. | 476 563 USD | COST PLUS FIXED FEE |
Bekijk de officiele bron (DECP - data.economie.gouv.fr) (USAS)